OEM Inquirydetail - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex
OEM Inquirydetail - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:
Product Detail
| Name | Eptifibatide |
| CAS number | 188627-80-7 |
| Molecular formula | C35H49N11O9S2 |
| Molecular weight | 831.96 |
| EINECS Number | 641-366-7 |
| Density | 1.60±0.1 g/cm3(Predicted) |
| Storage conditions | Sealed in dry, store in freezer, under -15°C |
Synonyms
Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).
Platelet Glycoprotein Antagonist
Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.
Classification
Classification of Antiplatelet Aggregation Drugs
Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.
Product detail pictures:
Related Product Guide:
Our company sticks into the basic principle of "Quality is definitely the life of the business, and status may be the soul of it" for OEM Inquirydetail - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Ecuador, Hyderabad, Cambodia, Due to the stability of our products, timely supply and our sincere service, we are able to sell our products not only over the domestic market, but also exported to countries and regions, including the Middle East, Asia, Europe and other countries and regions. At the same time, we also undertake OEM and ODM orders. We will do our best to serve your company, and establish a successful and friendly cooperation with you.
By Joyce from Surabaya - 2017.03.28 16:34
We always believe that the details decides the company's product quality, in this respect, the company conform our requirements and the goods are meet our expectations.
By Chris Fountas from Venezuela - 2017.08.21 14:13
